
- CB1 Allosteric Enhancers
- CB1 Allosteric Inhibitors
- GPR55 Antagonists
- A Novel Target for Diastolic Heart Failure
- Novel Fungal Diagnostics and Therapeutics
- CB1 Receptor PET Ligands
- Rheumatoid Arthritis
- Antifungal Agents: chitin synthase inhibitors
- A Novel Treatment for Hypertension
- PET Tracers for Alzheimer's Disease
- Insulin Gene Therapy
- HIV Entry Inhibitors
- A Novel Target for Prostate Cancer
- A Novel Anthelmintic Target
- Neuroprotective Agents
- Hypothalamic Receptors for Metabolic Health
- SBF: Delivery of drugs across the BBB using shark VNAR biotools
- 18F-FDR as a New Powerful Radiolabelling Agent for PET
- PET Tracers for Hypoxia
- Angiogenesis Tracers
- Development of PET Tracers for Membrane Transporters
- A Novel Retinoid Pathway
Rheumatoid Arthritis
We have recently spun out a company, OsteoRx Ltd, and a project in which we discovered novel therapies for rheumatoid arthritis, is being commercialised by Modern Biosciences
In a field dominated by expensive biological agents, we discovered a series of small molecule inhibitors which have therapeutic potential for the treatment of a number of inflammatory and autoimmune disorders, including rheumatoid arthritis, inflammatory bowel disease and psoriasis.
Funding: Knowledge Transfer Grant (2001), Scottish Enterprise Proof of Concept (2002), Royal Society of Edinburgh Enterprise Fellowship (2003), Scottish Enterprise Proof of Concept Follow-on (2005), Arthritis and Rheumatism Campaign (2005), NESTech (2006), Modern Biosciences (2008)
Project Team: Dr Iain Greig

University of Aberdeen
King's College
Aberdeen
AB24 3FX
